ZCM
JAZZ icon

Zebra Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Zebra Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,333
Closed -$254K – 288
2016
Q4 		$254K Sell
2,333
-4,441
-66% -$495K 0.08% 251
2016
Q3 		$823K Buy
6,774
+696
+11% +$93.8K 0.26% 180
2016
Q2 		$859K Buy
+6,078
New +$896K 0.3% 172

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Zebra Capital Management's JAZZ Position: Q1 2017 in Review

Zebra Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 2,333 shares — an estimated $254K sold.

Zebra Capital Management first reported a position in JAZZ in Q2 2016 and held it in 3 quarters. The position peaked at $859K in Q2 2016. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

  • Zebra Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Zebra Capital Management sold 2,333 Jazz Pharmaceuticals shares in Q1 2017, an estimated $254K.
  • Zebra Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Zebra Capital Management's Jazz Pharmaceuticals position peaked at $859K in Q2 2016.
  • 306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on Zebra Capital Management's 13F filing for Q1 2017, filed 12 May 2017.